ObsEva (OBSV) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free OBSV Stock Alerts Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.comamericanbankingnews.com - May 6 at 2:44 AMObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listinglobenewswire.com - April 3 at 1:00 AMObsEva Announces Update on Board of Directorsglobenewswire.com - March 19 at 2:00 AMObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023globenewswire.com - February 28 at 1:00 AMObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Datesbenzinga.com - February 26 at 12:34 AMObsEva SA OBSNmorningstar.com - November 11 at 10:37 PMObsEva SA OBSEFmorningstar.com - November 11 at 7:36 AMObsEva (NASDAQ: OBSV)fool.com - June 18 at 11:34 PMObsEva Files Year End 2022 Financial Statementsfinance.yahoo.com - March 31 at 5:48 PMObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023finance.yahoo.com - March 15 at 5:57 AMObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim Chairmanmarkets.businessinsider.com - March 13 at 4:46 PMObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerlandfinance.yahoo.com - March 13 at 7:04 AMWhy Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com - March 3 at 2:19 PMWhy Is ObsEva (OBSV) Stock Up 93% Today?investorplace.com - March 3 at 9:21 AMWhy ObsEva (OBSV) Stock Is Down 36% Todayinvestorplace.com - February 24 at 11:16 AMObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerlandfinance.yahoo.com - February 24 at 3:11 AMObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filinguk.finance.yahoo.com - January 12 at 1:02 PMObsEva Announces Dismissal of Moratorium Proceedingsfinance.yahoo.com - December 19 at 7:58 AMObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filingfinance.yahoo.com - December 14 at 4:00 AMObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimatesfinance.yahoo.com - December 1 at 9:11 PMObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Updatefinance.yahoo.com - December 1 at 4:10 PMObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedingsfinance.yahoo.com - October 27 at 12:52 AMObsEva SA (OBSV)finance.yahoo.com - October 16 at 6:41 PMObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of Nolasibanmarkets.businessinsider.com - October 14 at 10:02 AMObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo Financefinance.yahoo.com - October 13 at 1:31 PMObsEva Says Partner Yuyuan Bioscience Obtained Regulatory Nod for Nolasiban Drug Trial in China - Marketscreener.commarketscreener.com - October 13 at 8:31 AMObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - Benzingabenzinga.com - October 13 at 8:31 AMObsEva's Chinese Partner Wins Regulatory Nod To Launch Early-stage Trial Of Clinical Pregnancy Drug - Marketscreener.commarketscreener.com - October 13 at 1:49 AMObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswireglobenewswire.com - October 13 at 1:49 AMObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in Chinafinance.yahoo.com - October 13 at 1:49 AMOBSV.PH - Obseva SA | Stock Price & Latest News | Reutersreuters.com - October 6 at 8:07 AMObsEva Flat on Restructuring Initiatives - Baystreet.cabaystreet.ca - September 15 at 5:16 AMAfter FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Stafffinance.yahoo.com - September 13 at 1:11 PMObsEva Announces Progress on Restructuring Initiatives - GlobeNewswireglobenewswire.com - September 13 at 3:10 AMOBSV.O - Obseva SA | Stock Price & Latest News | Reutersreuters.com - September 11 at 10:33 AMOBSV.N - Obseva SA | Stock Price & Latest News | Reutersreuters.com - September 10 at 8:40 AMThis Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'finance.yahoo.com - September 7 at 5:20 AMHot Penny Stocks For Your Buy List in September? 3 to Watch - StreetInsider.comstreetinsider.com - August 31 at 8:57 PMBluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know By Benzinga - Investing.com UKuk.investing.com - August 31 at 8:57 PMGlobal Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs - OXO-001 (Oxolife) & Nolasiban (ObsEva) - ResearchAndMarkets.com - Business Wirebusinesswire.com - August 25 at 7:08 AMObsEva stock dips on Nasdaq non-compliance notice - Seeking Alphaseekingalpha.com - August 23 at 5:48 AMObsEva Receives Nasdaq Non-Compliance Notice - GlobeNewswireglobenewswire.com - August 22 at 4:45 AMObsEva Receives Nasdaq Non-Compliance Noticefinance.yahoo.com - August 22 at 4:45 AMOBSEVA : INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K - Marketscreener.commarketscreener.com - August 19 at 10:34 AMObsEva: Q2 Earnings Insights - Benzingabenzinga.com - August 18 at 3:14 PMObsEva Files Second Quarter 2022 Financial Statements - GlobeNewswireglobenewswire.com - August 17 at 6:33 PMObsEva Files Second Quarter 2022 Financial Statementsfinance.yahoo.com - August 17 at 6:33 PMKissei Pharmaceutical : Supplementary Explanatory Materials on Financial Results for the Three Months ended June 30, 2022 - Marketscreener.commarketscreener.com - August 5 at 5:37 AMAll You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy - Nasdaqnasdaq.com - August 3 at 6:29 PMAll You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buyfinance.yahoo.com - August 3 at 6:29 PM Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now OBSV Media Mentions By Week OBSV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OBSV News Sentiment▼0.000.58▲Average Medical News Sentiment OBSV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OBSV Articles This Week▼10▲OBSV Articles Average Week Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bionomics News Cyclerion Therapeutics News Addex Therapeutics News Chemomab Therapeutics News Tenax Therapeutics News NuCana News eFFECTOR Therapeutics News ASLAN Pharmaceuticals News Hepion Pharmaceuticals News Can-Fite BioPharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OBSV) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCollapse of the Petrodollar Colonial Metals[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
